{"id":68755,"date":"2026-11-07T01:27:32","date_gmt":"2026-11-07T01:27:32","guid":{"rendered":"https:\/\/cp.snarskis.lt\/index.php\/2026\/11\/07\/svedu-mucolife-therapeutics-gavo-91-tukst-euru-spartins-lopl-vaisto-mlt-001-gamyba\/"},"modified":"2026-11-07T01:27:32","modified_gmt":"2026-11-07T01:27:32","slug":"svedu-mucolife-therapeutics-gavo-91-tukst-euru-spartins-lopl-vaisto-mlt-001-gamyba","status":"publish","type":"post","link":"https:\/\/cp.snarskis.lt\/index.php\/2026\/11\/07\/svedu-mucolife-therapeutics-gavo-91-tukst-euru-spartins-lopl-vaisto-mlt-001-gamyba\/","title":{"rendered":"\u0160ved\u0173 \u201eMucoLife Therapeutics\u201c gavo 91 t\u016bkst. eur\u0173: spartins LOPL vaisto \u201eMLT-001\u201c gamyb\u0105"},"content":{"rendered":"<p>\u0160vedijos biotechnologij\u0173 \u012fmon\u0117 \u201eMucoLife Therapeutics\u201c gavo 91 000 eur\u0173 (1 mln. \u0160vedijos kron\u0173) finansavim\u0105, skirt\u0105 pl\u0117sti jos kuriamo vaisto nuo l\u0117tin\u0117s obstrukcin\u0117s plau\u010di\u0173 ligos (LOPL) gamyb\u0105.<\/p>\n<p>L\u0117\u0161as skyr\u0117 \u0160vedijos inovacij\u0173 agent\u016bra \u201eVinnova\u201c pagal program\u0105, orientuot\u0105 \u012f param\u0105 ma\u017eoms ir vidutin\u0117ms \u012fmon\u0117ms, besinaudojan\u010dioms gyvyb\u0117s moksl\u0173 infrastrukt\u016bra.<\/p>\n<p>Finansavimas bus nukreiptas \u012f gamybos proceso suk\u016brim\u0105 ir parengim\u0105 mastelio didinimui \u201eMLT-001\u201c \u2013 \u012fkvepiamam peptidui, kuris kuriamas siekiant tirpdyti kv\u0117pavimo tak\u0173 gleivi\u0173 kam\u0161\u010dius sergant LOPL.<\/p>\n<p>Bendrov\u0117 pabr\u0117\u017eia, kad gleivi\u0173 kam\u0161\u010diai aptinkami daugiau nei pusei pacient\u0173, sergan\u010di\u0173 vidutinio sunkumo ar sunkia LOPL, o patvirtintos terapijos, tiesiogiai nukreiptos \u012f \u0161\u012f rei\u0161kin\u012f, \u0161iuo metu n\u0117ra.<\/p>\n<h2>Kas yra \u201eMLT-001\u201c ir koki\u0105 problem\u0105 taikosi spr\u0119sti<\/h2>\n<p>Pasak \u012fmon\u0117s, gleivi\u0173 sukelta kv\u0117pavimo tak\u0173 obstrukcija yra susijusi su prastesn\u0117mis ligos baigtimis: ma\u017eesne plau\u010di\u0173 funkcija, da\u017enesniais pa\u016bm\u0117jimais ir didesniu mirtingumu.<\/p>\n<p>\u201eMucoLife Therapeutics\u201c teigia, kad \u0161\u012f ligos aspekt\u0105 galima taikyti kaip potencial\u0173 gydymo taikin\u012f, siekiant pagerinti pacient\u0173 b\u016bkl\u0119.<\/p>\n<p>Bendrov\u0117s atliktas darbas parod\u0117, kad \u201eMLT-001\u201c sintez\u0117 yra pritaikoma didesniam mastui, o dabar skirtas finansavimas pad\u0117s vystyti jau didesn\u0117s apimties gamybos proces\u0105.<\/p>\n<h2>Bendradarbiavimas su gamybos partneriu ir pasirengimas GMP etapui<\/h2>\n<p>Planuojama, kad procesas bus kuriamas glaud\u017eiai bendradarbiaujant su sutartine vaist\u0173 k\u016brimo ir gamybos organizacija (CDMO).<\/p>\n<p>Projekto tikslas \u2013 pasiekti tinkam\u0105 produkto grynumo lyg\u012f ir u\u017etikrinti dokumentuot\u0105 i\u0161eig\u0105, kad gamybos procesas b\u016bt\u0173 patikimas bei atkuriamas.<\/p>\n<p>Taip pat numatoma parengti perkeliam\u0105 proceso apra\u0161\u0105 ir kontrol\u0117s strategij\u0105, kuri v\u0117lesniuose etapuose b\u016bt\u0173 naudojama gamybai pagal geros gamybos praktikos (GMP) reikalavimus.<\/p>\n<p>\u012emon\u0117s vadovas Thaher Pelaseyed pabr\u0117\u017e\u0117, kad b\u016btent gamyba yra etapas, kuris \u201eperspektyvi\u0105 molekul\u0119 paver\u010dia vaistu\u201c, o \u201eVinnova\u201c parama leis vystyti \u201eMLT-001\u201c valymo proces\u0105 ir priart\u0117ti prie klinikini\u0173 tyrim\u0173.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u0160ved\u0173 \u201eMucoLife Therapeutics\u201c gavo 91 t\u016bkst. eur\u0173 i\u0161 \u201eVinnova\u201c, kad i\u0161pl\u0117st\u0173 LOPL gydymui kuriamo \u012fkvepiamo peptido \u201eMLT-001\u201c gamyb\u0105.<\/p>\n","protected":false},"author":0,"featured_media":68756,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[7],"tags":[4093,83,23727,34013,53933,53935,53934],"miestas":[],"class_list":["post-68755","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technologijos","tag-biotechnologijos","tag-fintech","tag-letine-obstrukcine-plauciu-liga","tag-lopl","tag-mucolife-therapeutics","tag-vaistu-gamyba","tag-vinnova"],"acf":[],"_links":{"self":[{"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/posts\/68755","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/comments?post=68755"}],"version-history":[{"count":0,"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/posts\/68755\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/media\/68756"}],"wp:attachment":[{"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/media?parent=68755"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/categories?post=68755"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/tags?post=68755"},{"taxonomy":"miestas","embeddable":true,"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/miestas?post=68755"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}